Merck’s Antiretroviral Isentress More Efficient In Suppressing HIV Among Untreated Patients

Merck’s antiretroviral drug Isentress suppresses levels of HIV in previously untreated patients better than the company’s antiretroviral efavirenz, according to research presented Sunday at a meeting of the American Society of Microbiology and the Infectious Diseases Society of America,

More: continued here

Filed under: HIV / AIDS on October 29th, 2008